These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 2851995

  • 41. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients.
    Formelli F, Carsana R, Costa A, Buranelli F, Campa T, Dossena G, Magni A, Pizzichetta M.
    Cancer Res; 1989 Nov 01; 49(21):6149-52. PubMed ID: 2529028
    [Abstract] [Full Text] [Related]

  • 42. Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen.
    Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC.
    Anticancer Res; 1992 Nov 01; 12(4):1147-53. PubMed ID: 1386970
    [Abstract] [Full Text] [Related]

  • 43. Retinoids as chemopreventive agents for breast cancer.
    Moon RC, Mehta RG, Detrisac CJ.
    Cancer Detect Prev; 1992 Nov 01; 16(1):73-9. PubMed ID: 1551141
    [Abstract] [Full Text] [Related]

  • 44. Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention.
    Cope MB, Steele VE, Lubet RA, Eto I, Juliana MM, Hill DL, Grubbs CJ.
    Oncol Rep; 2004 Feb 01; 11(2):465-9. PubMed ID: 14719085
    [Abstract] [Full Text] [Related]

  • 45. Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells.
    Mehta RR, Hawthorne ME, Graves JM, Mehta RG.
    Eur J Cancer; 1998 May 01; 34(6):902-7. PubMed ID: 9797705
    [Abstract] [Full Text] [Related]

  • 46. Inhibition of mammary and urinary bladder carcinogenesis by a retinoid and a maleic anhydride-divinyl ether copolymer (MVE-2).
    McCormick DL, Becci PJ, Moon RC.
    Carcinogenesis; 1982 May 01; 3(12):1473-6. PubMed ID: 6217919
    [Abstract] [Full Text] [Related]

  • 47. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats.
    Ratko TA, Detrisac CJ, Dinger NM, Thomas CF, Kelloff GJ, Moon RC.
    Cancer Res; 1989 Aug 15; 49(16):4472-6. PubMed ID: 2525951
    [Abstract] [Full Text] [Related]

  • 48. Tolerability of the synthetic retinoid Fenretinide (HPR).
    Costa A, Malone W, Perloff M, Buranelli F, Campa T, Dossena G, Magni A, Pizzichetta M, Andreoli C, Del Vecchio M.
    Eur J Cancer Clin Oncol; 1989 May 15; 25(5):805-8. PubMed ID: 2525470
    [Abstract] [Full Text] [Related]

  • 49. p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action.
    Takahashi N, Watanabe Y, Maitani Y, Yamauchi T, Higashiyama K, Ohba T.
    Int J Cancer; 2008 Feb 01; 122(3):689-98. PubMed ID: 17955489
    [Abstract] [Full Text] [Related]

  • 50. beta-Carotene reduces sister chromatid exchanges induced by chemical carcinogens in mouse mammary cells in organ culture.
    Manoharan K, Banerjee MR.
    Cell Biol Int Rep; 1985 Sep 01; 9(9):783-9. PubMed ID: 2931184
    [Abstract] [Full Text] [Related]

  • 51. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate.
    Bhatnagar R, Abou-Issa H, Curley RW, Koolemans-Beynen A, Moeschberger ML, Webb TE.
    Biochem Pharmacol; 1991 May 15; 41(10):1471-7. PubMed ID: 1826840
    [Abstract] [Full Text] [Related]

  • 52. Distribution of fenretinide in the mammary gland of breast cancer patients.
    Mehta RG, Moon RC, Hawthorne M, Formelli F, Costa A.
    Eur J Cancer; 1991 May 15; 27(2):138-41. PubMed ID: 1827276
    [Abstract] [Full Text] [Related]

  • 53. Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats.
    Swanson BN, Zaharevitz DW, Sporn MB.
    Drug Metab Dispos; 1980 May 15; 8(3):168-72. PubMed ID: 6104581
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.